• HREC approval received for Phase IIa clinical trial of Xolatryp in heart attack patients
• Preclinical animal studies initiated to assess Xolatryp's efficacy in oncology
• Sound financial position with AU$7.12 million cash balance at 31 December 2025

Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company developing TRPC ion channel inhibitors, has announced its Quarterly Activities Report and Appendix 4C for the three months ending 31 December 2025. Key highlights include:Xolatryp® Program Phase IIa Clinical Trial: Nyrada received HREC approval to conduct a Phase IIa clinical trial assessing the safety and preliminary efficacy of Xolatryp in heart attack patients undergoing angioplasty with stenting. Patient recruitment is expected to commence in March 2026.Research and Development: Nyrada plans to initiate a series of preclinical animal studies to assess the efficacy of Xolatryp in oncology indications.Finance, Capital and Corporate: Nyrada had a cash balance of AU$7.12 million at 31 December 2025 and expects to receive an AU$2.16 million R&D tax rebate for FY2025. The company also received funds from director participation in a capital raise and exercise of options.Nyrada was granted a trademark for Xolatryp in class 5 (medicinal, health, or pharmaceutical goods) and class 44 (health, medical, or wellness services).